S
Sahar Saeed
Researcher at McGill University
Publications - 39
Citations - 877
Sahar Saeed is an academic researcher from McGill University. The author has contributed to research in topics: Hepatitis C & Population. The author has an hindex of 14, co-authored 33 publications receiving 731 citations. Previous affiliations of Sahar Saeed include McGill University Health Centre.
Papers
More filters
Journal ArticleDOI
HCV‐specific T cells in HCV/HIV co‐infection show elevated frequencies of dual Tim‐3/PD‐1 expression that correlate with liver disease progression
Bahareh Vali,R. Brad Jones,Ali Sakhdari,Prameet M. Sheth,Kiera L. Clayton,Feng-Yun Yue,Gabor Gyenes,David Wong,Marina B. Klein,Sahar Saeed,Erika Benko,Colin Kovacs,Rupert Kaul,Rupert Kaul,Mario A. Ostrowski,Mario A. Ostrowski +15 more
TL;DR: It is demonstrated that co‐expression of Tim‐3 and PD‐1 may play a significant role in HCV‐specific T‐cell dysfunction, especially in the setting of HIV co‐infection.
Journal ArticleDOI
Cohort Profile: The Canadian HIV–Hepatitis C Co-infection Cohort Study
Marina B. Klein,Sahar Saeed,Hong Yang,Jeffrey I. Cohen,Brian Conway,Curtis Cooper,Pierre Côté,Joseph Cox,John Gill,David Haase,Shariq Haider,Julio S. G. Montaner,Neora Pick,Anita Rachlis,Danielle Rouleau,Roger Sandre,Mark W. Tyndall,Sharon Walmsley +17 more
TL;DR: The growing burden of chronic HCV infection is expected to result in dramatic increases in the rates of cirrhosis, liver failure, hepatocellular carcinoma, transplant needs and related annual healthcare costs in Canada and worldwide.
Journal ArticleDOI
Impact of hepatitis C viral replication on CD4+ T-lymphocyte progression in HIV-HCV coinfection before and after antiretroviral therapy.
TL;DR: It is found that CD4 cell progression is negatively affected by the presence of ongoing HCV replication in coinfected individuals initiating ART which persisted throughout stable ART suggesting active HCV infection affects immune restoration even after years of ART exposure.
Journal ArticleDOI
How Generalizable Are the Results From Trials of Direct Antiviral Agents to People Coinfected With HIV/HCV in the Real World?
Sahar Saeed,Erin Strumpf,Sharon Walmsley,Sharon Walmsley,Kathleen C. Rollet-Kurhajec,Neora Pick,Valérie Martel-Laferrière,Mark W. Hull,M. John Gill,Joseph Cox,Curtis Cooper,Marina B. Klein,Marina B. Klein,Jeffrey I. Cohen,Brian Conway,Pierre Côté,John Gill,Shariq Haider,Marianne Harris,David Haase,Julio S. G. Montaner,Erica E. M. Moodie,Erica E. M. Moodie,Anita Rachlis,Danielle Rouleau,Roger Sandre,Joseph Mark Tyndall,Marie-Louise Vachon,Sharon Walmsley,Sharon Walmsley,David Wong +30 more
TL;DR: It is found the majority of coinfected patients were not included in clinical trials of direct-acting antivirals, raising concerns about the generalizability of these trial results.
Journal ArticleDOI
Restrictions for reimbursement of direct-acting antiviral treatment for hepatitis C virus infection in Canada: a descriptive study
Alison D. Marshall,Sahar Saeed,Lisa Barrett,Curtis Cooper,Carla Treloar,Julie Bruneau,Jordan J. Feld,Lesley Gallagher,Marina B. Klein,Mel Krajden,Naglaa H. Shoukry,Lynn E. Taylor,Jason Grebely +12 more
TL;DR: A review of criteria of reimbursement of HCV direct-acting antivirals in Canada showed substantial interjurisdictional heterogeneity, which could inform health policy and support the development and adoption of a national HCV strategy.